Concise Prescribing Info Full Prescribing Info Contents Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Indications/Uses

In conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) ≥30 kg/m², or overweight patients (BMI ≥28 kg/m²) with associated risk factors eg, type II diabetes, hyperlipidemia and hypertension. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to loose at least 5% of their body weight as measured at the start of drug therapy.

Xenical Indications/Uses

orlistat

Manufacturer:

Cheplapharm

Distributor:

The Glory Medicina

DKSH